Merch
Medical card
A busy week in cannabis policy saw the U.S. federal rescheduling process generate fresh state-level ripples, Congress advance several cannabis and drug-related bills, and Europe’s regulatory landscape shift on multiple fronts.
United States
Alabama Withdraws Rescheduling Objection, Aligning State With Federal Move
Alabama’s public health officials this week withdrew their previously filed objection to rescheduling marijuana under state law, characterizing the move as procedural and consistent with the Trump administration’s federal rescheduling effort. The development is notable because Alabama’s medical cannabis program is already operational despite marijuana remaining Schedule I under state law, a tension officials acknowledged directly. As the federal rescheduling process continues to near finalization, state agencies across the country are increasingly being forced to reconcile their own scheduling frameworks with Washington’s direction.
The Cannigma’s Take: A nice example of how Washington can effectively move state drug legislation in a kind of administrative domino effect.
DEA Emerges as De Facto Cannabis Regulator Under Rescheduling
An analysis published this week argues that the Drug Enforcement Administration is quietly assuming a regulatory role over cannabis businesses as a consequence of rescheduling, a shift that operators are only beginning to absorb. The piece, from attorneys at Mandelbaum Barrett PC, notes that cannabis companies built around state compliance frameworks are now encountering federal oversight expectations they were not designed to meet. This follows a newsletter item from September 14 reporting that the DEA has already been pressuring at least one medical cannabis business over employees with prior convictions, suggesting the regulatory posture is not theoretical.
The Cannigma’s Take: Uneven federalisation is a potential risk here, with reports from operators indicating that DA field divisions have been asking different supplemental questions and approaching inspections differently.
Congress Advances Multiple Cannabis and Drug Bills
The House passed a bill this week requiring the Department of Health and Human Services to study how prevalent drug testing for marijuana, fentanyl, and other substances is in hospital emergency departments. Separately, two new bipartisan bills were introduced: the CLAIM Act, which would shield insurance companies from federal penalties for covering state-legal cannabis businesses, and a bill that would bar the federal government from denying jobs or security clearances based on past marijuana use. The cluster of legislative activity reflects continued congressional interest in cannabis-adjacent reform even as the rescheduling process dominates the federal agenda.
The Cannigma’s Take: Routine hospital toxicology screens commonly test for marijuana while missing fentanyl, which often requires separate testing. Congress is now trying to make overdose testing catch up with the actual overdose crisis.
Supreme Court Asked to Resolve Cannabis Licensing Residency Dispute
A petition was filed this week asking the U.S. Supreme Court to take up a challenge to state cannabis licensing laws that favor in-state residents over out-of-state applicants. The petitioner, who was denied licenses in both Washington State and Sacramento, California, argues that such residency preferences are unconstitutional. Lower courts have split on the question, making it a candidate for Supreme Court review. The outcome could have significant consequences for how states structure their licensing regimes.
The Cannigma’s Take: The constitutional question is bigger than residency preferences: does federal prohibition give states permission to discriminate in a market those same states have chosen to legalise?
Michigan Industry Backs GOP Governor Candidate Over Tax Rollback Pledge
Michigan’s cannabis trade association endorsed the Republican gubernatorial candidate ahead of November’s election, citing his pledge to repeal or significantly reduce a recently enacted wholesale tax on the industry. The endorsement is a striking illustration of how cannabis tax policy is reshaping political alignments at the state level, with industry groups prioritizing economic relief over traditional partisan affiliations.
The Cannigma’s Take: Repealing Michigan’s cannabis tax means finding money for roads, not merely winning an argument about cannabis. The 24% levy was built into a major infrastructure funding package and dedicated to the Neighborhood Road Fund, so the industry is now competing against a politically popular use for hundreds of millions in anticipated revenue.
Massachusetts Ballot Measure Draws Labor Opposition
The Service Employees International Union Massachusetts State Council formally endorsed the campaign against a November ballot measure that would roll back the state’s marijuana legalization law. The union’s entry into the fight adds organized labor’s weight to the opposition coalition. The measure has been a recurring subject in recent weeks, and the SEIU endorsement marks a significant escalation in the campaign against it.
The Cannigma’s Take: Massachusetts voters are not being offered conventional prohibition. Question 8 would preserve limited adult possession and gifting while dismantling the regulated recreational supply chain. That is an unusually awkward middle ground.
San Francisco Proposes Rules for Cannabis Cafes
San Francisco officials released draft regulations this week for cannabis consumption cafes, where patrons could consume cannabis while attending live music events and ordering food. The proposal follows the city’s Board of Supervisors approving a framework in July, itself enabled by a California state law enacted last year. The city is now seeking public comment on the draft rules.
The Cannigma’s Take: San Francisco is treating cafés as cannabis-industry rescue policy as much as nightlife reform. Ordinary restaurants and bars cannot simply add cannabis, while existing licensed cannabis businesses get the first crack at café permits.
Trump-Linked PAC Channels Cannabis Donations to Anti-Legalization Lawmakers
A political action committee sharing a treasurer with President Trump’s super PAC has been using cannabis industry donations to fund campaign advertising for 11 vulnerable Republican House members, including several who have voted against cannabis legalization legislation. The arrangement highlights a tension between the industry’s financial interests in maintaining political access and its stated policy goals.
The Cannigma’s Take: The striking feature here the concentration of the money: roughly $11.5 million reportedly came from six large cannabis-linked donors into a vehicle free to spend on a much broader Republican agenda. That is cannabis politics becoming ordinary corporate influence politics.
Europe and UK
UK CBD Food Approvals Imminent, But EU Alignment Could Complicate Them
Britain is on the verge of issuing its first authorizations for CBD food products after a regulatory process that has stretched six years, with the UK Food Standards Agency recommending approval of three applications. However, the approvals may have a limited shelf life: the UK is preparing to align its food safety framework more closely with the European Union, and incoming EU rules on CBD foods could effectively supersede the newly granted approvals. The situation leaves businesses facing continued uncertainty even as the first approvals arrive.
The Cannigma’s Take: The deeper UK-EU problem is not merely whose approval stamp applies: the safety benchmarks are diverging. The FSA has been working with a provisional CBD limit of 10mg per day, while EFSA’s 2026 assessment equates to roughly 2mg for a 70kg adult.
German Court Rejects Insurance Coverage for Medical Cannabis Flowers
A German court ruled against a patient on benefits with a severe neurological condition who sought to continue receiving medical cannabis flowers through statutory health insurance. The ruling underscores ongoing tensions in Germany’s post-legalization landscape between expanded personal use rights and the practical limits of insurance reimbursement for medical cannabis, a gap that has been a persistent friction point in the German market.
The Cannigma’s Take: This ruling is less a contradiction of German legalisation than evidence that recreational law and healthcare policy are now moving on separate tracks. Germany liberalised adult cannabis, then in July deliberately removed cannabis flower from statutory health-insurance reimbursement as part of a cost-control package. This makes product easier to possess, while making medically prescribed flower harder for poorer patients to afford.
France Advances Domestic Medical Cannabis Production
French biotech PGP Farmer has selected five cannabis cultivars from a 30-variety Dutch phenotyping trial for cultivation at its planned 9-hectare EU-GMP production site in the Dordogne region. The selection is a concrete step toward France establishing domestic medical cannabis supply as the country works toward the regulatory reforms needed for a full commercial rollout. France has been building toward a regulated medical market for several years, and this agronomic groundwork signals the production side is advancing in parallel with the policy process.
The Cannigma’s Take: France may be building supply faster than it is building a market. Its own health ministry has stressed that routine access still depends on further scientific and administrative steps, while HAS has been running a separate reimbursement evaluation; a large EU-GMP cultivation project can therefore be technically ready before there is a stable pool of reimbursed prescriptions to serve.
Rest of World
Argentina expanded its hemp regulatory framework this week, with the national regulator ARICCAME establishing a new commercial licensing system that adds flowers and biomass to a market previously focused on seed, grain, and fiber, all under a 1% THC limit. Meanwhile, New Zealand’s hemp association launched a seed distribution program to put hemp cultivation within reach of ordinary citizens following the country’s liberalization of small-scale, non-commercial growing rules. Both moves reflect a broader pattern of Southern Hemisphere countries incrementally broadening their hemp frameworks at the production and supply level.
Contradictions and Tensions
The most significant tension this week runs through the U.S. federal rescheduling process. Alabama’s withdrawal of its scheduling objection is framed as procedural alignment with federal direction, yet the state’s own officials noted that their medical cannabis program is already operating while marijuana remains Schedule I under state law. This illustrates a broader contradiction: the federal rescheduling process is being held up as a legitimizing force for the industry, but the DEA’s concurrent moves to scrutinize cannabis businesses over employee backgrounds suggest that federal legitimacy is arriving with enforcement strings attached, not simply with relief.
Sign up for bi-weekly updates, packed full of cannabis education, recipes, and tips. Your inbox will love it.
